2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

PhytoHealth Corporation

Company Presentations

Wednesday, July 22 Company Presentations 1–Pharma

PhytoHealth Corporation

Company Info

Name /PhytoHealth Corporation

Address /FL. 5-1, No.167, FuHsing N. RD. Taipei 105, Taiwan, R. O. C.

Website /www.phytohealth.com.tw/en

Presenter

Name /Jasmine Lin

Title /Vice President

Email /jasmine.lin@phytohealth.com.tw

Telephone /(Work) 02-25453697#2106

Fax /02-25140245

Mobile /0930932091

Company Type

Pharmaceutical

About the Company

PhytoHealth is the 1st Publicly Listed BioPharm Company in Taiwan. Our main product- PG2 Lyo. injection 500mg is the 1st New Botanical Drug License issued by TFDA. We built the 1st PIC/S GMP Botanical Drug API Plant Certified by TFDA. We focus on the R&D and application of APS (Astragalus Polysaccharides) for more than 20 years and have developed a prescription drug-PG2 Lyo. injection 500mg and a serial of nutraceutical products. We are looking for worldwide distributors of our products and the partners of co-development with our product pipelines. Please link to: http://www.phytohealth.com.tw/en/product/product_medicine to know more.

Brief Description of main products or services

PG2 Lyo. Injection 500 mg is an IV injectable isolated, extracted and partial purified from the Astragalus membranaceus active fraction. Clinically proven to be safe for enhancing three-lineage WBC, RBC and platelet counts recovery, and treating cancer-related fatigue (CRF) syndrome among cancer patients. The existing pharmacological and clinical studies showed:

  • Restoring blood cell counts and enhancing immunity
  • Prolonging Immunocompromised mice survival after virus infection
  • Enhancing megakaryocyte proliferation and maturation
  • Prophylaxis of neutropenia
  • Improving quality of life among cancer patient

PG2 Lyo Injection has been approved by TFDA as drug therapy for cancer-related fatigue disease among advanced cancer patients (TFDA Drug Permit NO 054853). More than 40 major medical centers and hospitals in Taiwan have listed PG2. More than 200 oncologists prescribed PG2 and 3000 patients once took the treatment.

Extended indications in clinical stages are: (1) Preventing Chemotherapy Toxicities: multicenter Phase II clinical trial ongoing; (2) Idiopathic Thrombocytopenic Purpura (ITP) : completed the US FDA Phase II study (FDA IND No. 105,738) and granted US FDA orphan drug designation (orphan drug designation # 12-3659); (3) Hemorrhagic Stroke: completed the pilot study (Sci Rep. 2017 Mar 31;7:45628).   

APS related nutraceutical products: EnerCharge® capsule, EnerCharge® Drink, AmazPowerTM

Contact Person

Name /Jasmine Lin

Email /jasmine.lin@phytohealth.com.tw

Phone /(Work) 02-25453697#2106